Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1

The Lancet Infectious Diseases

Volumn 12, Issue 12, 2012, Pages 966-976

  Whitaker, Jennifer A ^a,b   Rouphael, Nadine G ^a   Edupuganti, Srilatha ^a   Lai, Lilin ^a   Mulligan, Mark J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MIXED INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS REPLICATION;

FEMALE; GUIDELINES AS TOPIC; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MALE; VACCINATION;

EID: 84869770264     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70243-8     Document Type: Review

References (101)

1. Alter MJ Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44(1 suppl):S6-S9.
2. Global Health Observatory: HIV/AIDS World Health Organization, (accessed Aug 24, 2012). http://www.who.int/gho/hiv/en/.
3. Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat 2010, 17:879-886.
4. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003, 188:571-577.
5. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005, 34:121-130.
6. Lewden C, May T, Rosenthal E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008, 48:590-598.
7. Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43:27-34.
8. Thio CL Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009, 49(5 suppl):S138-S145.
9. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
10. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009, 58:1-207.
11. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006, 55:1-33.
12. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008, 9:82-88.
13. Guidelines Version 6 - October 2011 European AIDS Clinical Society, (accessed Aug 24, 2012). http://europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EACSGuidelines-v6.0-English.pdf.
14. Geretti AM, Brook G, Cameron C, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008, 9:795-848.
15. Tedaldi EM, Baker RK, Moorman AC, et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004, 38:1478-1484.
16. Assad S, Francis A Over a decade of experience with a yeast recombinant hepatitis B vaccine. Vaccine 1999, 18:57-67.
17. Hashemi B, Mahdavi-Mazdeh M, Abbasi M, Hosseini-Moghaddam SM, Zinat NH, Ahmadi F Efficacy of HBV vaccination in various stages of chronic kidney disease: is earlier better?. Hepat Mon 2011, 11:816-820.
18. Fabrizi F, Dixit V, Bunnapradist S, Martin P Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther 2006, 23:1105-1112.
19. Liu YL, Kao MT, Huang CC A comparison of responsiveness to hepatitis B vaccination in patients on hemodialysis and peritoneal dialysis. Vaccine 2005, 23:3957-3960.
20. Khan AN, Bernardini J, Rault RM, Piraino B Low seroconversion with hepatitis B vaccination in peritoneal dialysis patients. Perit Dial Int 1996, 16:370-373.
21. Bel'eed K, Wright M, Eadington D, Farr M, Sellars L Vaccination against hepatitis B infection in patients with end stage renal disease. Postgrad Med J 2002, 78:538-540.
22. Fabrizi F, Dixit V, Martin P, Messa P Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther 2011, 33:815-821.
23. Alavian SM, Tabatabaei SV The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. Vaccine 2010, 28:3773-3777.
24. Fisman DN, Agrawal D, Leder K The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002, 35:1368-1375.
25. McDermott AB, Cohen SB, Zuckerman JN, Madrigal JA Human leukocyte antigens influence the immune response to a pre-S/S hepatitis B vaccine. Vaccine 1999, 17:330-339.
26. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989, 321:708-712.
27. Michel ML, Tiollais P Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol (Paris) 2010, 58:288-295.
28. Hollinger FB Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989, 87:36S-40S.
29. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993, 270:2935-2939.
30. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000, 18:1161-1165.
31. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005, 41:1045-1048.
32. Ungulkraiwit P, Jongjirawisan Y, Atamasirikul K, Sungkanuparph S Factors for predicting successful immune response to hepatitis B vaccination in HIV-1 infected patients. Southeast Asian J Trop Med Public Health 2007, 38:680-685.
33. Paitoonpong L, Suankratay C Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy. Scand J Infect Dis 2008, 40:54-58.
34. Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008, 19:600-604.
35. Bailey CL, Smith V, Sands M Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis 2008, 12:e77-e83.
36. Landrum ML, Huppler Hullsiek K, Ganesan A, et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009, 27:4731-4738.
37. Pettit NN, DePestel DD, Malani PN, Riddell J Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients. HIV Clin Trials 2010, 11:332-339.
38. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis 2011, 203:984-991.
39. Plotkin SA, Orenstein WA Vaccines, 4th edn 2004, Saunders, Philadelphia, PA, USA.
40. Immunization Standards. WHO prequalified vaccines World Health Organization, (accessed Aug 24, 2012). http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html.
41. Van Damme P, Kane M, Meheus A Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. BMJ 1997, 314:1033-1036.
42. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980, 303:833-841.
43. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine. Report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982, 97:362-366.
44. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC What level of hepatitis B antibody is protective?. J Infect Dis 1999, 179:489-492.
45. Hadler SC, Judson FN, O'Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991, 163:454-459.
46. Jilg W, Schmidt M, Deinhardt F Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989, 160:766-769.
47. Gesemann M, Scheiermann N Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995, 13:443-447.
48. Jilg W, Schmidt M, Deinhardt F Decline of anti-HBs after hepatitis B vaccination and timing of revaccination. Lancet 1990, 335:173-174.
49. Honorati MC, Palareti A, Dolzani P, Busachi CA, Rizzoli R, Facchini A A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B. Clin Exp Immunol 1999, 116:121-126.
50. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986, 315:209-214.
51. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009, 200:1390-1396.
52. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010, 28:730-736.
53. Poorolajal J, Mahmoodi M, Majdzadeh R, Nasseri-Moghaddam S, Haghdoost A, Fotouhi A Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 28:623-631.
54. Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010, 24:545-555.
55. Cruciani M, Mengoli C, Serpelloni G, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009, 27:17-22.
56. Moir S, Fauci AS B cells in HIV infection and disease. Nat Rev Immunol 2009, 9:235-245.
57. Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005, 19:1947-1955.
58. Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010, 116:5571-5579.
59. Titanji K, De Milito A, Cagigi A, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006, 108:1580-1587.
60. Mehta N, Cunningham CK, Flynn P, et al. Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine 2010, 28:3672-3678.
61. Goncalves L, Albarran B, Salmen S, et al. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 2004, 326:20-28.
62. Bi X, Suzuki Y, Gatanaga H, Oka S High frequency and proliferation of CD4+ FOXP3+ Treg in HIV-1-infected patients with low CD4 counts. Eur J Immunol 2009, 39:301-309.
63. del Pozo Balado Mdel M, Leal M, Mendez Lagares G, et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010, 202:362-369.
64. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006, 107:3925-3932.
65. Banatvala JE, Van Damme P Hepatitis B vaccine - do we need boosters?. J Viral Hepat 2003, 10:1-6.
66. Bauer T, Jilg W Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24:572-577.
67. Dentico P, Crovari P, Lai PL, et al. Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres. Vaccine 2002, 20:3725-3730.
68. Wismans PJ, van Hattum J, Mudde GC, Endeman HJ, Poel J, de Gast GC Is booster injection with hepatitis B vaccine necessary in healthy responders? A study of the immune response. J Hepatol 1989, 8:236-240.
69. Wainwright RB, McMahon BJ, Bulkow LR, Parkinson AJ, Harpster AP Protection provided by hepatitis B vaccine in a Yupik Eskimo population. Seven-year results. Arch Intern Med 1991, 151:1634-1636.
70. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Recomm Rep 1991, 40:1-25. Recommendations of the Immunization Practices Advisory Committee (ACIP).
71. Leuridan E, Van Damme P Hepatitis B and the need for a booster dose. Clin Infect Dis 2011, 53:68-75.
72. Peces R, Laures AS Persistence of immunologic memory in long-term hemodialysis patients and healthcare workers given hepatitis B vaccine: role of a booster dose on antibody response. Nephron 2001, 89:172-176.
73. Chakvetadze C, Bani-Sadr F, Le Pendeven C, et al. Serologic response to hepatitis B vaccination in HIV-infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis 2010, 50:1184-1186.
74. Gandhi RT, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis 2005, 191:1435-1441.
75. Kamili S, Sozzi V, Thompson G, et al. Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model. Hepatology 2009, 49:1483-1491.
76. Locarnini SA, Yuen L Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 2010, 15:451-461.
77. Teo CG, Locarnini SA Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther 2010, 15:445-449.
78. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?. Bull World Health Organ 2010, 88:66-73.
79. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23:2902-2908.
80. Pasricha N, Datta U, Chawla Y, et al. Immune responses in patients with HIV infection after vaccination with recombinant hepatitis B virus vaccine. BMC Infect Dis 2006, 6:65.
81. Cornejo-Juarez P, Volkow-Fernandez P, Escobedo-Lopez K, Vilar-Compte D, Ruiz-Palacios G, Soto-Ramirez LE Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 2006, 3:9.
82. Veiga AP, Casseb J, Duarte AJ Humoral response to hepatitis B vaccination and its relationship with T CD45RA+ (naive) and CD45RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006, 24:7124-7128.
83. Potsch DV, Oliveira ML, Ginuino C, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine 2010, 28:1447-1450.
84. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011, 305:1432-1440.
85. Potsch DV, Camacho LA, Tuboi S, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine 2012, 30:5973-5977.
86. Landrum ML, Fieberg AM, Chun HM, et al. The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults. PLoS One 2010, 5:e8687.
87. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008, 197:292-294.
88. Bloom A, Jackson K, Kiviat A, Zheng H, Sax P, Gandhi R Repeat hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series. J Acquir Immune Defic Syndr 2009, 50:110-113.
89. Psevdos G, Kim JH, Groce V, Sharp V Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients. AIDS Patient Care STDS 2010, 24:403-407.
90. Boillat Blanco N, Probst A, Da Costa VW, et al. Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic. J Acquir Immune Defic Syndr 2011, 58:472-474.
91. Williams H, Bevan MA, Tong CY, Kulasegaram R Vaccination against hepatitis B in an HIV outpatients' department: an audit against national vaccination guidelines. Int J STD AIDS 2011, 22:405-406.
92. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment Pharmacol Ther 2006, 24:497-506.
93. Overton ET, Kang M, Peters MG, et al. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine 2010, 28:5597-5604.
94. Sasaki MG, Foccacia R, de Messias-Reason IJ Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine 2003, 21:4545-4549.
95. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008, 46:1310-1314.
96. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012, 30:2689-2696.
97. Tong NK, Beran J, Kee SA, et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int 2005, 68:2298-2303.
98. Tielemans CL, Vlasak J, Kosa D, et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011, 29:1159-1166.
99. Kong NC, Beran J, Kee SA, et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int 2008, 73:856-862.
100. Kundi M New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines 2007, 6:133-140.
101. Beran J Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008, 8:235-247.